Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.34−0.01 (-3.43%)
Close on Nov 17, 2026Market cap $36.53MP/E –Yield –
Caribou Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Caribou Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $85.77M, down 30.9% year over year. For fiscal 2025 it was $109.44M, down 15.9% from the year before. The highest annual figure on record is $130.15M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.44M | -15.9% |
| FY2024 | Dec 31, 2024 | $130.15M | +16.1% |
| FY2023 | Dec 31, 2023 | $112.08M | +36.3% |
| FY2022 | Dec 31, 2022 | $82.23M | +57.4% |
| FY2021 | Dec 31, 2021 | $52.26M | +51.8% |
| FY2020 | Dec 31, 2020 | $34.43M | +45.7% |
| FY2019 | Dec 31, 2019 | $23.64M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.94M | -31.6% |
| Q1 FY2026 | Mar 31, 2026 | $20.61M | -42.0% |
| Q4 FY2025 | Dec 31, 2025 | $23.82M | -21.8% |
| Q3 FY2025 | Sep 30, 2025 | $22.40M | -26.4% |
| Q2 FY2025 | Jun 30, 2025 | $27.69M | -22.0% |
| Q1 FY2025 | Mar 31, 2025 | $35.53M | +5.2% |
| Q4 FY2024 | Dec 31, 2024 | $30.46M | -2.6% |
| Q3 FY2024 | Sep 30, 2024 | $30.42M | +6.4% |
| Q2 FY2024 | Jun 30, 2024 | $35.48M | +33.9% |
| Q1 FY2024 | Mar 31, 2024 | $33.79M | +31.4% |
| Q4 FY2023 | Dec 31, 2023 | $31.28M | +21.5% |
| Q3 FY2023 | Sep 30, 2023 | $28.58M | +43.0% |
| Q2 FY2023 | Jun 30, 2023 | $26.50M | +17.4% |
| Q1 FY2023 | Mar 31, 2023 | $25.71M | +84.6% |
| Q4 FY2022 | Dec 31, 2022 | $25.74M | +70.3% |
| Q3 FY2022 | Sep 30, 2022 | $19.99M | +26.3% |
| Q2 FY2022 | Jun 30, 2022 | $22.58M | +83.2% |
| Q1 FY2022 | Mar 31, 2022 | $13.92M | +37.0% |
| Q4 FY2021 | Dec 31, 2021 | $15.11M | +25.7% |
| Q3 FY2021 | Sep 30, 2021 | $15.83M | +156.2% |
| Q2 FY2021 | Jun 30, 2021 | $12.33M | +62.6% |
| Q1 FY2021 | Mar 31, 2021 | $10.17M | +17.6% |
| Q4 FY2020 | Dec 31, 2020 | $12.02M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.18M | – |
| Q2 FY2020 | Jun 30, 2020 | $7.58M | – |
| Q1 FY2020 | Mar 31, 2020 | $8.64M | – |
See a number that looks wrong?